CN1118347A - 苯并五员杂环、其制法和作为药物和诊断药的用途 - Google Patents

苯并五员杂环、其制法和作为药物和诊断药的用途 Download PDF

Info

Publication number
CN1118347A
CN1118347A CN94109516A CN94109516A CN1118347A CN 1118347 A CN1118347 A CN 1118347A CN 94109516 A CN94109516 A CN 94109516A CN 94109516 A CN94109516 A CN 94109516A CN 1118347 A CN1118347 A CN 1118347A
Authority
CN
China
Prior art keywords
methyl
compound
hydrochloride
formylguanidine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94109516A
Other languages
English (en)
Chinese (zh)
Inventor
H·J·兰
A·威彻特
J-R·舒沃克
W·肖尔茨
U·阿尔博斯
P·克劳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4326005A external-priority patent/DE4326005A1/de
Priority claimed from DE19944414316 external-priority patent/DE4414316A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of CN1118347A publication Critical patent/CN1118347A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN94109516A 1993-08-03 1994-08-02 苯并五员杂环、其制法和作为药物和诊断药的用途 Pending CN1118347A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEP4326005.5 1993-08-03
DE4326005A DE4326005A1 (de) 1993-08-03 1993-08-03 Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DEP4414316.8 1994-04-25
DE19944414316 DE4414316A1 (de) 1994-04-25 1994-04-25 Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
CN1118347A true CN1118347A (zh) 1996-03-13

Family

ID=25928286

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94109516A Pending CN1118347A (zh) 1993-08-03 1994-08-02 苯并五员杂环、其制法和作为药物和诊断药的用途

Country Status (11)

Country Link
EP (1) EP0639573A1 (enExample)
JP (1) JPH07145149A (enExample)
KR (2) KR100343292B1 (enExample)
CN (1) CN1118347A (enExample)
AU (1) AU682371B2 (enExample)
CA (1) CA2129301A1 (enExample)
FI (1) FI943579L (enExample)
HU (1) HU218790B (enExample)
IL (1) IL110503A (enExample)
NO (1) NO301584B1 (enExample)
NZ (1) NZ264130A (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820132A (zh) * 2016-05-12 2016-08-03 广西师范大学 N-芳基苯并三唑类氮氧衍生物及其合成方法
CN105884675A (zh) * 2014-09-24 2016-08-24 中国药科大学 N-取代吲哚羧酸衍生物、其制法及医药用途
CN105968059A (zh) * 2016-05-12 2016-09-28 广西师范大学 N-烯基苯并三唑类氮氧衍生物及其制备方法和应用
CN110003079A (zh) * 2006-12-26 2019-07-12 兰休斯医疗成像公司 用于使心脏神经支配成像的配体
CN111960985A (zh) * 2018-08-08 2020-11-20 中国人民解放军总医院 抗肿瘤化合物
CN113967210A (zh) * 2020-07-24 2022-01-25 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
CA2121391A1 (en) * 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE69525763T2 (de) * 1994-04-11 2002-10-02 Chugai Seiyaku K.K., Tokio/Tokyo 4,6-DI-t-BUTYL-2,3-DIHYDROBENZOTHIOPHENE, DIE LDL OXIDATION HEMMEN
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
ES2135811T3 (es) * 1995-04-18 1999-11-01 Hoechst Ag Indenoil-guanidinas sustituidas antiarritmicas y cardioprotectoras.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
AU2193797A (en) * 1996-03-01 1997-09-16 Chiron Corporation Delivery of therapeutic agents to the prostate
JP2002502414A (ja) * 1997-06-02 2002-01-22 藤沢薬品工業株式会社 細胞中のＮａ▲上＋▼／Ｈ▲上＋▼交換の阻害剤としてのグアニジン誘導体
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
HU227568B1 (en) * 1997-12-24 2011-08-29 Sanofi Aventis Deutschland Indole derivatives, as inhibitors os factor xa
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
CA2260499A1 (en) * 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
CN1289326A (zh) * 1998-02-27 2001-03-28 辉瑞产品公司 用于治疗局部缺血的n－[(取代的五元二氮杂或三氮杂二不饱和环)羰基]胍衍生物
CN100378063C (zh) 1998-11-05 2008-04-02 富山化学工业株式会社 新型化合物及其医药用途
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
WO2000064445A1 (en) 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
WO2001044186A1 (en) 1999-12-16 2001-06-21 Sumitomo Pharmaceuticals Company, Limited Substituted guanidine derivatives
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
JP2004517851A (ja) 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
MXPA04008893A (es) 2002-03-13 2005-06-20 Array Biopharma Inc Derivados de bencimidazol n3 alquilados como inhibidores de mek.
FR2842526B1 (fr) * 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
FR2842525B1 (fr) * 2002-07-16 2005-05-13 Aventis Pharma Sa Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004092346A2 (en) 2003-04-15 2004-10-28 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction
FR2856062B1 (fr) * 2003-06-12 2005-11-11 Aventis Pharma Sa Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
KR20070028553A (ko) 2004-06-18 2007-03-12 바이올리폭스 에이비 염증 치료에 유용한 인돌
RU2007103834A (ru) 2004-07-01 2008-08-10 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) Ингибирование взаимодействия pdz-доменов малыми молекулами
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
JP4975641B2 (ja) * 2004-12-27 2012-07-11 コリア リサーチ インスティテュート オブ ケミカル テクノロジー ベンゾチオフェン−２−カルボニルグアニジン誘導体、その製造方法およびその誘導体を含む薬学的組成物
WO2006077366A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
KR100644385B1 (ko) * 2005-02-25 2006-11-10 동양수기산업(주) 흡입식 슬러지 수집기
JP5092746B2 (ja) 2005-08-08 2012-12-05 アステラス製薬株式会社 アシルグアニジン誘導体またはその塩
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
DE602006010433D1 (de) 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
AU2007206016A1 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
AU2007218781A1 (en) * 2006-02-20 2007-08-30 Astellas Pharma Inc. Amide derivative or salt thereof
ES2379734T3 (es) 2006-02-20 2012-05-03 Astellas Pharma Inc. Derivado de pirrol o sal del mismo
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
ES2679918T3 (es) 2010-02-18 2018-08-31 Vtv Therapeutics Llc Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
PT2707101T (pt) 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
EP3038618B1 (en) 2013-08-28 2020-10-14 Vanderbilt University Substituted indole mcl-1 inhibitors
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP6757312B2 (ja) 2014-03-27 2020-09-16 ヴァンダービルト ユニバーシティー 置換インドールｍｃｌ−１阻害剤
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
BR112018067775B1 (pt) 2016-03-04 2024-02-15 Vanderbilt University Compostos inibidores de mcl-1 indol substituídos, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
AU2022388555A1 (en) 2021-11-09 2024-05-02 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
KR102767180B1 (ko) 2024-10-17 2025-02-14 효림이엔아이 주식회사 슬러지 수집 안정성이 향상된 원형 슬러지 수집기

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
DE3304019A1 (de) * 1983-02-07 1984-08-09 Kali-Chemie Pharma Gmbh, 3000 Hannover 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DE4127026A1 (de) * 1991-08-16 1993-02-18 Boehringer Ingelheim Kg Neue pyrazinderivate, ihre herstellung und verwendung

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003079A (zh) * 2006-12-26 2019-07-12 兰休斯医疗成像公司 用于使心脏神经支配成像的配体
CN105884675A (zh) * 2014-09-24 2016-08-24 中国药科大学 N-取代吲哚羧酸衍生物、其制法及医药用途
CN105820132A (zh) * 2016-05-12 2016-08-03 广西师范大学 N-芳基苯并三唑类氮氧衍生物及其合成方法
CN105968059A (zh) * 2016-05-12 2016-09-28 广西师范大学 N-烯基苯并三唑类氮氧衍生物及其制备方法和应用
CN105820132B (zh) * 2016-05-12 2018-11-13 广西师范大学 N-芳基苯并三唑类氮氧衍生物及其合成方法
CN111960985A (zh) * 2018-08-08 2020-11-20 中国人民解放军总医院 抗肿瘤化合物
CN113967210A (zh) * 2020-07-24 2022-01-25 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途
WO2022017530A1 (zh) * 2020-07-24 2022-01-27 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途
CN113967210B (zh) * 2020-07-24 2025-02-07 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途

Also Published As

Publication number Publication date
AU6884494A (en) 1995-02-16
HU9402271D0 (en) 1994-09-28
KR100343292B1 (ko) 2002-12-26
IL110503A0 (en) 1994-10-21
FI943579A7 (fi) 1995-02-04
HUT70547A (en) 1995-10-30
IL110503A (en) 2000-06-29
KR950005817A (ko) 1995-03-20
NO942864L (no) 1995-02-06
HU218790B (hu) 2000-12-28
FI943579A0 (fi) 1994-08-01
CA2129301A1 (en) 1995-02-04
NO942864D0 (enExample) 1994-08-02
NO301584B1 (no) 1997-11-17
EP0639573A1 (de) 1995-02-22
NZ264130A (en) 1995-12-21
JPH07145149A (ja) 1995-06-06
FI943579L (fi) 1995-02-04
KR950005512A (ko) 1995-03-20
AU682371B2 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
CN1118347A (zh) 苯并五员杂环、其制法和作为药物和诊断药的用途
CN1073988C (zh) 取代的杂芳酰胍、其制法、药用及含有它们的药品
US5852046A (en) Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
CN1068308C (zh) 取代的苯甲酰胍、其制法和含有它们的药物及应用
CN1064954C (zh) 邻位取代的苯甲酰胍、制法、含有它们的药品及用途
US6271247B1 (en) Hydrazide compounds
CN1295213C (zh) 氟化环烷基衍生的苯甲酰基胍及其作为药物的用途
CN1053899C (zh) 酰基胍，其制备方法和应用以及含有这类化合物的药物组合物
JP4323803B2 (ja) 置換２−アニリノーベンゾイミダゾール及びｎｈｅ阻害剤としてのその使用
SK3542003A3 (en) Substituted cinnamic acid guanidides, method for the production thereof, their use as a medicament, and to a medicament containing these compounds
CN1060763C (zh) 脲取代的苯甲酰胍、制法和用途及含苯甲酰胍的药物
EP2291352B1 (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
CN1122329A (zh) 含氟的苯基取代链烯羧酰胍、制法、药用及其药品
CN1057760C (zh) 氨基酸取代的苯甲酰胍，其制备方法，用途及含有它们的药物
CN1212255A (zh) 联苯磺酰基氨基氰、其制备方法及其作为药物的用途
JP2017132781A (ja) ベンゾチアゾロン化合物
CN1117045A (zh) 取代的二环杂芳酰胍、其制法、药用以及含有它们的药品
CN1119183A (zh) 邻氨基取代的苯甲酰胍、其制备方法、药用以及药品
SK13196A3 (en) Alkalicly substituted benzoylguanidines, manufacturing process thereof, their use as drug or diagnostic agent and drugs containing these compositions
JP2005533038A (ja) 置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬
HUP0103184A2 (hu) Szulfonil-bifenil-metil-szubsztituált imidazolszármazékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
CN1063436C (zh) 氟烷基/链烯基取代的苯甲酰基胍，其制备方法和用途
CN1057759C (zh) 烷基－5－甲基磺酰基苯甲酰胍衍生物
JP4630270B2 (ja) Ｎ−置換（ベンゾイミダゾール−２−イル）フェニルアミン、それらの製造方法、医薬又は診断剤としてのそれらの使用及び該物質を含有する医薬
CN100339079C (zh) 取代的咪唑烷类化合物,其制备方法,其作为药物或诊断剂的用途以及含有取代的咪唑烷类化合物的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication